Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0452 Transporter Info
Gene Name SLC6A2
Transporter Name Sodium-dependent noradrenaline transporter
Gene ID
6530
UniProt ID
P23975
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Cocaine

            6 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cocaine inhibits the transportation of Dopamine by SLC6A2 [1]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-NET

  DT Modulation 2

 Cocaine inhibits the transportation of Mazindol by SLC6A2 [2]

Affected Drug/Substrate

 Mazindol Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 3

 Cocaine inhibits the transportation of Norepinephrine by SLC6A2 [3]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 4

 Cocaine inhibits the transportation of RTI-55 by SLC6A2 [2] , [4]

Affected Drug/Substrate

 RTI-55 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 5

 Cocaine inhibits the activity of SLC6A2 [5] , [6]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 6

 Cocaine inhibits the activity of SLC6A2 [1]

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-NET

  Fluoxetine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fluoxetine inhibits the transportation of Dopamine by SLC6A2 [7]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-NET

  DT Modulation 2

 Fluoxetine inhibits the transportation of Norepinephrine by SLC6A2 [3] , [8] , [9]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 3

 Fluoxetine inhibits the activity of SLC6A2 [13] , [14]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Mazindol

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mazindol inhibits the transportation of Mazindol by SLC6A2 [2]

Affected Drug/Substrate

 Mazindol Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 2

 Mazindol inhibits the transportation of RTI-55 by SLC6A2 [2]

Affected Drug/Substrate

 RTI-55 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 3

 Mazindol inhibits the activity of SLC6A2 [5]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Desipramine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desipramine inhibits the transportation of Nisoxetine by SLC6A2 [11]

Affected Drug/Substrate

 Nisoxetine Modulation Type Inhibition

  DT Modulation 2

 Desipramine inhibits the transportation of Norepinephrine by SLC6A2 [12]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

  DT Modulation 3

 Desipramine inhibits the activity of SLC6A2 [15]

Cell System

 Madin-Darby Canine Kidney (MDCK) cells-NET

  Reboxetine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Reboxetine inhibits the transportation of Nisoxetine by SLC6A2 [18] , [19]

Affected Drug/Substrate

 Nisoxetine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 2

 Reboxetine inhibits the activity of SLC6A2 [23]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Duloxetine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Duloxetine inhibits the transportation of Nisoxetine by SLC6A2 [19]

Affected Drug/Substrate

 Nisoxetine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 2

 Duloxetine inhibits the activity of SLC6A2 [20] , [21] , [22]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Amitriptyline

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amitriptyline inhibits the transportation of Norepinephrine by SLC6A2 [3]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 2

 Amitriptyline inhibits the activity of SLC6A2 [25] , [26]

  Venlafaxine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Venlafaxine inhibits the transportation of Norepinephrine by SLC6A2 [3] , [9]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 2

 Venlafaxine inhibits the activity of SLC6A2 [22]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  4-Fluoroamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-Fluoroamphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.2 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  4-Fluoromethamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-Fluoromethamphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.22 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  alpha-Pyrrolidinopentiophenone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 alpha-Pyrrolidinopentiophenone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.02 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Amphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.07 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Ephedrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ephedrine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.32 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Methamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methamphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.14 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Citalopram

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Citalopram inhibits the transportation of Dopamine by SLC6A2 [7] , [27]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-NET

  Dextroamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dextroamphetamine inhibits the transportation of Norepinephrine by SLC6A2 [3]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Dopamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dopamine inhibits the activity of SLC6A2 [28]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Methylphenidate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methylphenidate inhibits the activity of SLC6A2 [29]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Bupropion

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bupropion inhibits the activity of SLC6A2 [6]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Protriptyline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Protriptyline inhibits the activity of SLC6A2 [30]

Cell System

 Chinese hamster ovary (CHO) cells-NET

  Desvenlafaxine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desvenlafaxine inhibits the activity of SLC6A2 [22]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Norepinephrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Norepinephrine inhibits the expression of SLC6A2 [32]

  Carmustine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carmustine increases the expression of SLC6A2 [33]

  Copper Sulfate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Copper Sulfate increases the expression of SLC6A2 [35]

  Zidovudine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zidovudine increases the expression of SLC6A2 [36]

  Belinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Belinostat increases the expression of SLC6A2 [37]

  Imipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Imipramine inhibits the activity of SLC6A2 [38] , [39]

  Atomoxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Atomoxetine inhibits the activity of SLC6A2 [40] , [41]

  Amfepramone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amfepramone inhibits the activity of SLC6A2 [42] , [43]

  Sibutramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sibutramine modulates the activity of SLC6A2 [44]

  Tapentadol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tapentadol modulates the activity of SLC6A2 [45]

  Trimipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Trimipramine inhibits the activity of SLC6A2 [46]

  Acetaminophen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acetaminophen inhibits the activity of SLC6A2 [47]

  Maprotiline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Maprotiline inhibits the activity of SLC6A2 [48]

  Amoxapine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amoxapine inhibits the activity of SLC6A2 [49]

  Desvenalfaxine succinate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desvenalfaxine succinate inhibits the activity of SLC6A2 [50]

  Levomilnacipran

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Levomilnacipran modulates the activity of SLC6A2 [51]

  Phenmetrazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenmetrazine inhibits the activity of SLC6A2 [52]

  Milnacipran

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Milnacipran inhibits the activity of SLC6A2 [53]

  Phentermine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phentermine inhibits the activity of SLC6A2 [54]

  Iobenguane I-123

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Iobenguane I-123 inhibits the activity of SLC6A2 [55]

  Paroxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Paroxetine inhibits the activity of SLC6A2 [56]

  Haloperidol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Haloperidol inhibits the activity of SLC6A2 [57]

  Clomipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clomipramine inhibits the activity of SLC6A2 [58]

  Vorinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vorinostat induces the activity of SLC6A2 [59]

Drug Marketed but not Approved by US FDA

  Zinc Sulfate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zinc Sulfate increases the expression of SLC6A2 [34]

Drug in Phase 4 Trial

  Hypericum

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Hypericum inhibits the activity of SLC6A2 [74]

Drug in Phase 3 Trial

  Vitamin E

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vitamin E inhibits the expression of SLC6A2 [61]

  Triclosan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triclosan increases the expression of SLC6A2 [63]

  Bupropion + naltrexone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bupropion + naltrexone inhibits the activity of SLC6A2 [67]

  Dasotraline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dasotraline inhibits the activity of SLC6A2 [68]

  Roclatan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Roclatan modulates the activity of SLC6A2 [69]

  Suronacrine maleate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Suronacrine maleate modulates the activity of SLC6A2 [72]

  Bicifadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bicifadine modulates the activity of SLC6A2 [73]

  Amitifadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amitifadine inhibits the activity of SLC6A2 [75] , [76]

  BI 201335

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 BI 201335 inhibits the activity of SLC6A2 [77]

Drug in Phase 2 Trial

  DOV 21947

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 DOV 21947 inhibits the activity of SLC6A2 [70] , [71]

Drug in Phase 1 Trial

  CCRIS-9277

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 CCRIS-9277 inhibits the activity of SLC6A2 [64]

  Sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sodium arsenite inhibits the expression of SLC6A2 [66]

Investigative Drug

  Nisoxetine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nisoxetine inhibits the transportation of Dopamine by SLC6A2 [7]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-NET

  DT Modulation 2

 Nisoxetine inhibits the transportation of Norepinephrine by SLC6A2 [8] , [9] , [10]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 3

 Nisoxetine inhibits the activity of SLC6A2 [16]

  Pyrovalerone

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pyrovalerone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.05 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  DT Modulation 2

 Pyrovalerone inhibits the activity of SLC6A2 [24]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.16 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.97 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Methcathinone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methcathinone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.12 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Methylenedioxypyrovalerone (MDPV)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methylenedioxypyrovalerone (MDPV) inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.04 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  R-Norduloxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 R-Norduloxetine inhibits the activity of SLC6A2 [31]

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

Drug Withdrawn

  Naphyrone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Naphyrone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.11 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

Natural Product

  4-Fluoroephedrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-Fluoroephedrine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 4.5 microM) [17]

Affected Drug/Substrate

 Norepinephrine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-NET

  Selenium nanoparticles

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Selenium nanoparticles inhibits the expression of SLC6A2 [61]

Acute Toxic Substance

  Antimycin A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Antimycin A increases the expression of SLC6A2 [65]

Health and Environmental Toxicant

  1-methyl-4-phenylpyridinium

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 1-methyl-4-phenylpyridinium affects the expression of SLC6A2 [60]

  Lead

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lead inhibits the expression of SLC6A2 [62]
References
1 Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg Med Chem. 2007 Jun 15;15(12):4159-74.
2 Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. J Med Chem. 2017 Apr 13;60(7):3109-3123.
3 An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3411-5.
4 Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors. J Med Chem. 1999 Sep 9;42(18):3647-56.
5 Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4097-109.
6 Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
7 From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J Med Chem. 2008 May 22;51(10):3045-8.
8 Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2013 Oct 15;23(20):5515-8.
9 Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3234-7.
10 Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors. J Med Chem. 2012 Sep 27;55(18):8188-92.
11 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. J Med Chem. 2009 Sep 24;52(18):5703-11.
12 Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). J Med Chem. 2010 Jun 10;53(11):4511-21.
13 Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
14 Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. J Med Chem. 2009 Mar 26;52(6):1530-9.
15 Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1834-8.
16 Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 15;18(18):4929-31.
17 Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 2015 Mar;25(3):365-76.
18 [4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1795-8.
19 Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2562-6.
20 Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
21 N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5078-81.
22 Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. ACS Med Chem Lett. 2013 May 7;4(6):560-4.
23 Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter. J Med Chem. 2009 Jan 8;52(1):62-73.
24 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
25 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
26 A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90.
27 A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter. Bioorg Med Chem Lett. 2013 Jan 1;23(1):323-6.
28 Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4133-7.
29 Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
30 First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain. J Med Chem. 2012 Apr 12;55(7):3488-501.
31 Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
32 Regulation of the human norepinephrine transporter by cocaine and amphetamine. J Pharmacol Exp Ther. 2000 Dec;295(3):951-9.
33 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
34 Discrimination of vanadium from zinc using gene profiling in human bronchial epithelial cells. Environ Health Perspect. 2005 Dec;113(12):1747-54.
35 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
36 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23.
37 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
38 Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83.
39 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
40 New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2004 Nov;9(2):293-302.
41 Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50.
42 Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
43 Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7.
44 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
45 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
46 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
47 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Jun 11.
48 Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
49 Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
50 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
51 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
52 Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
53 Milnacipran: Beyond a Role of Antidepressant. Clin Neuropharmacol. 2009 Jun 10.
54 Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
55 Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
56 Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. J Med Chem. 2005 Sep 22;48(19):6023-34.
57 Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4294-7.
58 Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34.
59 Improving cytocompatibility of CdTe quantum dots by Schiff-base-coordinated lanthanides surface doping. J Nanobiotechnology. 2018 Apr 19;16(1):43.
60 Dependence on electron transport chain function and intracellular signaling of genomic responses in SH-SY5Y cells to the mitochondrial neurotoxin MPP(+). Exp Neurol. 2003 May;181(1):25-38.
61 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
62 Correlations of gene expression with blood lead levels in children with autism compared to typically developing controls. Neurotox Res. 2011 Jan;19(1):1-13.
63 Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
64 Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR. Neurotoxicology. 2019 May;72:95-100.
65 Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615.
66 Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer. Arch Toxicol. 2021 Jul;95(7):2351-2365.
67 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
68 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
69 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
70 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
71 1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors. Bioorg Med Chem. 2011 Jun 1;19(11):3451-61.
72 Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
73 Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
74 The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8.
75 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J Med Chem. 2010 Mar 25;53(6):2534-51.
76 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
77 Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother. 2010 Nov;54(11):4611-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.